Oxford Cannabinoid Technologies reports no adverse events in OCT461201 trial

VideoArticle

25 Sept

Written By Rob Bennett

https://www.proactiveinvestors.co.uk/companies/news/1027529/oxford-cannabinoid-technologies-reports-no-adverse-events-in-oct461201-trial-1027529.html

Rob Bennett https://www.oxcantech.com

Final Dose Administered

Oxford Canabinoid Tech. Complete Phase 1 Clinical Trials on Programme 1 for CIPN Treatment